title: TCR diversity - a universal cancer immunotherapy biomarker?
abstract: Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that can identify patients who benefit from these therapies. In a recent manuscript by Sheikh and colleagues, the investigators evaluated changes in T cell clonality in the peripheral blood and tumors of patients treated with sipuleucel-T using next generation sequencing of T cell receptor Vß CDR3 sequences. Their findings are discussed in the context of this trial and other cancer immunotherapies.
authors.affiliation: University of Wisconsin Carbone Cancer Center, 7007 Wisconsin Institutes for Medical Research, 1111 Highland Avenue, Madison, WI 53705 USA.
authors.forename: Douglas G
authors.initials: DG
authors.lastname: McNeel
mesh_terms: D000818:Animals; D015415:Biomarkers; D014644:Genetic Variation; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000235:genetics* / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D011948:Receptors, Antigen, T-Cell / Q000235:genetics* / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D011948:Receptors, Antigen, T-Cell
keywords: Prostate cancer; Sipuleucel-T; T-cell diversity; TCR sequencing; Tumor vaccine